Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Research To Practice | Oncology Videos · Nov 29, 2025 · 58m

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics:

Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)

SERD Monotherapy (13:34)

SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)

SERDs for "Molecular Progression" — The SERENA-6 Study (41:25)

CME information and select publications